Janssen Reports P-II Study (SunRISe-1) Results of TAR-200 for the Treatment of Patients with BCG-Unresponsive HR-NMIBC CIS
Shots:
- The company highlighted the first results from the P-II study evaluating TAR-200 monotx. and cetrelimab monotx. in 200 patients with Bacillus Calmette-Guérin (BCG)-unresponsive HR-NMIBC who are ineligible for or decline, radical cystectomy
- The results showed that patients treated with TAR-200 & cetrelimab monotx. achieved the 1EPs of a CR (72.7% & 38.1%) & the results were presented at AUA 2023. Additionally, initial results showed low rates of grade ≥3 AEs and limited no. of treatment discontinuations due to AEs were reported
- TAR-200, a novel investigational intravesical drug delivery system & cetrelimab is an investigational anti-PD-1 mAb. TAR-200 is being studied in (SunRISe-2) & (SunRISe-4) trials for muscle-invasive bladder cancer
Ref: PR Newswire | Image: Janssen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
